PatientsVille.com Logo

CONFUSIONAL STATE and Celexa

PatientsVille

CONFUSIONAL STATE Symptoms and Causes

What kind of medical care would you want if you were too ill or hurt to express your wishes? Advance directives are legal documents that allow you to spell out your decisions about end-of-life care ahead of time. They give you a way to tell your wishes to family, friends, and health care professionals and to avoid confusion later on.

A living will tells which treatments you want if you are dying or permanently unconscious. You can accept or refuse medical care. You might want to include instructions on

  • The use of dialysis and breathing machines
  • If you want to be resuscitated if your breathing or heartbeat stops
  • Tube feeding
  • Organ or tissue donation

A durable power of attorney for health care is a document that names your health care proxy. Your proxy is someone you trust to make health decisions for you if you are unable to do so.

NIH: National Cancer Institute

Check out the latest treatments for CONFUSIONAL STATE

CONFUSIONAL STATE treatment research studies

Celexa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Celexa Side Effects

Dizziness (136)
Nausea (135)
Anxiety (127)
Suicidal Ideation (124)
Depression (123)
Headache (120)
Completed Suicide (120)
Pain (111)
Insomnia (109)
Feeling Abnormal (102)
Vomiting (101)
Diarrhoea (99)
Fall (96)
Fatigue (91)
Loss Of Consciousness (89)
Tremor (89)
Dyspnoea (85)
Agitation (78)
Confusional State (76)
Aggression (69)
Asthenia (38)
Convulsion (34)
Suicide Attempt (33)
Condition Aggravated (32)
Abnormal Behaviour (32)
Weight Increased (31)
Somnolence (30)
Anger (30)
Pulmonary Embolism (28)
Malaise (28)
Chest Pain (28)
Crying (27)
Irritability (27)
Abdominal Pain Upper (25)
Abdominal Pain (25)
Constipation (25)
Overdose (25)
Serotonin Syndrome (25)
Paraesthesia (25)
Syncope (24)
Amnesia (24)
Hyperhidrosis (24)
Intentional Self-injury (22)
Hypertension (21)
Arthralgia (21)
Injury (20)
Palpitations (20)
Heart Rate Increased (20)
Blood Pressure Increased (20)
Rash (19)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Can ratio-citalopram be taken long term with Lectopam 6 mg?

Celexa triggered my tourettes syndrome. Three weeks after starting this med, I started having motor and vocal tics. Do not advise anyone to take this drug. It sucks.

I need to find out if Celexa is available in Ecuador as I will be living there for several months. Thanks.

I Took celexa for about 7 years im a 28 year old male. A couple months after getting off of the drug I have been twitching all over my body. Feet, legs,thighs,arms,stomach,hands,face,everywhere. I also have this feeling of a lump stuck in my throat.

It probably didn't trigger your TS. It was probably just supressing symptoms to a point where they were un noticable. Celexa is something they use to help alleviate the symptoms. so when you came off of it, they came back. They could have developed w

iBefore starting Nucynta I had some very bad sides effects of insomina. I had two occasions of getiing up from sleeping(more like tossing and turning all nite) for several days and being in a trance like state. Husband drove me the doctor he felt

Thankyou for witing out this article I have been on 120mgs of Zeldox since November 2010 at first it seemed to work and now it has me stuck in a depression state . I was prior to that on olanzapine which held me also in a depressed state I

31 years old female, I usesibutramina and feel overwhelmed, palpitations, thirsty all the time, insomnia, bad humor, headaches,an state of euphoria

After 2 bad nights sleep from an awful cough, I bought Delsym. Long story short....I woke up from a nightmare where I was dying, and awakened to a weird state of consciousness, being OBSESSED with my tongue, which I sensed was swelling in m

Are there anticougulant treatment in Namibia state hospitals?

Are there anticougulant treatment in state hospitals of Namibia?

Back in 1991 while in Texas, I was given a scopolamine patch to wear overnight in order to prevent nausea from general anesthesia given for outpatient surgery. I put the patch behind my ear before going to bed and woke up 2 hours later in a state of

By a doctors mistake i was prescribed 650mg a day over six weeks, i was in a terrible state would this of caused any long term dammage

Coricidin induced in me a 3-day-state of depression like I never had before. I later found that Coricidin may interfere with serotonin metabolism and that is most likely the reason for that effect.

Dear sir I want to inform that in using gliclazid in a patient with mild degree of hepatosplenomegally diagnosed as mild liver cirrhosis the patient state is detorated and develop mild ascites and moderate to severe lower limbe oedema

CONFUSIONAL STATE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting EScitalopram PIndolol ONset of Action
Condition: Unipolar Depression
Interventions: Drug: escitalopram, pindolol;   Drug: escitalopram
Outcome Measures: MADRS score change between baseline and 2 weeks of treatment;   Response/remission (MADRS) at 6 weeks;   Adverse events;   Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups
2 Recruiting Lexapro®'s Efficacy After Dose Escalation in Remission Study
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram
Outcome Measures: Montgomery-Åsberg Depression Rating Scale (MADRS);   Hamilton Depression Rating Scale-17 items (HAM-D);   Hamilton Anxiety Rating Scale (HAM-A);   Clinical Global Impression-severity (CGI-S);   Clinical Global Impression-Improvement (CGI-I);   Beck's Depression Inventory(BDI);   WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF);   Clinically Useful Depression Outcome Scale (CUDOS);   Short From-36 Health survey (SF-36 Health survey)
3 Unknown  Circadian Effects of Escitalopram
Condition: Depression
Intervention: Drug: placebo/escitalopram
Outcome Measures: Resetting effect of Escitalopram on the circadian pacemaker;   Correlation between improvement in depression with Escitalopram and the degree of realignment between the timing of sleep and the timing of the biological clock.
4 Recruiting Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Conditions: Major Depressive Disorder;   Major Depressive Disorder, Recurrent, Unspecified;   Major Depressive Disorder, Single Episode, Unspecified
Interventions: Drug: Escitalopram oxalate;   Device: transcranial direct current stimulation
Outcome Measures: Change in Hamilton Rating Scale for Depression, 17 items (HAMD17);   Change in Montgomery-Asberg Depression Rating Scale (MADRS);   Change in Beck Depression Inventory (BDI);   Hamilton Rating Scale for Depression, 17 items (HAMD17)
5 Recruiting Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder
Conditions: Irritable Bowel Syndrome;   Panic Disorder
Intervention: Drug: Escitalopram
Outcome Measures: Gastrointestinal Symptom Rating Scale (GSRS).;   State Trait Anxiety Inventory (STAI).
6 Unknown  Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Conditions: Low Back Pain;   Depression
Interventions: Drug: Escitalopram;   Drug: Placebo
Outcome Measures: In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment.;   In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment.;   In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment.;   Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning.;   Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning.
7 Recruiting DECIFER: DEpression and Citalopram In First Episode Recovery
Conditions: Schizophrenia;   Schizophreniform Disorder
Interventions: Drug: Citalopram;   Behavioral: Psychoeducation;   Behavioral: Cognitive Behavioral Therapy (CBT);   Radiation: Functional Magnetic Resonance Imaging (fMRI);   Drug: Placebo
Outcome Measures: Calgary Depression Scale for Schizophrenia (CDSS);   Scale for the Assessment of Negative Symptoms (SANS);   Brief Psychiatric Rating Scale (BPRS);   InterSePT Scale for Suicidal Thinking (ISST);   Heinrich Quality of Life Scale (QOL)
8 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.
9 Unknown  Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)
Condition: Major Depression
Interventions: Drug: escitalopram;   Drug: nortriptyline
Outcome Measures: Hamilton depression rating scale;   Drop out due to side-effects of drugs
10 Recruiting Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Condition: Alcohol Dependence
Intervention: Drug: citalopram
Outcome Measures: Craving for alcohol in type B alcohol dependence with citalopram compared to placebo;   Striatal dopamine receptor availability in type B alcohol dependence with citalopram, compared to placebo
11 Unknown  The Effects of Escitalopram on Cytokines
Condition: Depression
Intervention: Drug: Escitalopram
Outcome Measures: The changes in cytokines;   The changes in Hamilton Depression Rating Scale
12 Recruiting Brain Aging and Treatment Response in Geriatric Depression
Conditions: Mild Neurocognitive Disorder;   MCI;   Depression
Interventions: Drug: Escitalopram;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale (HDRS) scores;   Change in cognitive domain scores
13 Unknown  Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
Conditions: Depression;   Continuous Antidepressant Abuse;   Adverse Reaction to Drug
Intervention: Drug: Escitalopram
Outcome Measures: antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks;   biological value at 0 week and 8 weeks
14 Not yet recruiting The ISLAND Study: InSuLa Assessed Needs for Depression
Condition: Depression
Interventions: Drug: Escitalopram;   Behavioral: Cognitive Behavioral Therapy;   Other: Combination treatment (Escitalopram + CBT)
Outcome Measures: Remission from major depressive episode;   Response to treatment
15 Unknown  Citalopram for Cocaine Dependence
Condition: Cocaine Dependence
Interventions: Drug: Citalopram;   Drug: Placebo
Outcome Measures: Abstinence;   Cocaine Use Days;   Cocaine-negative Urines;   Retention in Treatment
16 Recruiting A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
Condition: Depressive Disorder, Major
Intervention: Drug: Escitalopram
Outcome Measures: Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF);   Change From Baseline in Sheehan Disability Scale (SDS);   Remission Rate at Week 8;   Onset of Effect Rate at Week 1;   Onset of Effect Rate at Week 2;   Change From Baseline to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Scores;   Change From Baseline to Week 8 in Hamilton Anxiety Scale (HAMA) Scores;   Change From Baseline to Week 8 in Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) Scores
17 Unknown  Cipralex® for Anxiety Disorders in Adolescents
Condition: Anxiety Disorder
Intervention: Drug: Cipralex®
Outcome Measures: Treatment Efficacy;   Physiological response to stress;   Suicide risk
18 Recruiting Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Condition: Healthy Young and Elderly Volunteers
Interventions: Drug: Intravenous Citalopram;   Drug: Normal Saline
Outcome Measures: BOLD fMRI Response;   Genetics and Cognitive/Emotional Change
19 Unknown  Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression
Condition: Chronic Depression
Interventions: Other: CBASP psychotherapy;   Drug: Escitalopram
Outcome Measures: Depressive symptomatology after 8 weeks after randomization as measured by the MADRS;   Depressive symptoms and remission 28 weeks after randomization; social, interpersonal and work function 28 weeks after randomization
20 Unknown  Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
Condition: Marijuana Dependence
Intervention: Drug: Escitalopram
Outcome Measures: Clean urine THC samples;   Questionnaire ratings of anxiety and depression and withdrawal symptoms